Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 3Active not recruiting 3

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 5Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 5Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1

Interventions

pembrolizumab 35Magnetic Resonance Spectroscopy 32Specimen Handling 31Carboplatin 24Radiotherapy 22Biopsy 21Nivolumab 20Radiation 19Cisplatin 19Cyclophosphamide 18Paclitaxel 17Doxorubicin 14Radiotherapy, Intensity-Modulated 13Bevacizumab 13olaparib 12Leucovorin 12Docetaxel 12durvalumab 11Taxes 11Gemcitabine 11Disulfides 11Dexamethasone 11Vincristine 10Radiosurgery 10Prednisone 10Pemetrexed 10Immunoglobulin G 10Fluorouracil 9Etoposide 9enzalutamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Lenalidomide × 30 days × Clear all
NCT01351896 2026-05-27

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
49 enrolled 34 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05032820 2026-05-19

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Medical College of Wisconsin

Phase 2 Completed
40 enrolled 32 charts
Plasma cell

Hematologic Diseases, Multiple Myeloma

NCT03934684 2026-05-11

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Amgen

Phase 4 Completed
101 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT03901963 2026-05-08

AURIGA

Janssen Research & Development, LLC

Phase 3 Active not recruiting
200 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT04126200 2026-05-06

DREAMM 5

GlaxoSmithKline

Phase 1/2 Active not recruiting
208 enrolled 5 charts
Plasma cell

Multiple Myeloma

NCT03477539 2026-05-05

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Mayo Clinic

Phase 2 Completed
49 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡